Author: admin

DelveInsight’s, “Soft Tissue Sarcoma Pipeline Insight 2024” report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from Soft Tissue Sarcoma Pipeline Report

• DelveInsight’s Soft Tissue Sarcoma pipeline report depicts a robust space with 125+ active players working to develop 130+ pipeline therapies for Soft Tissue Sarcoma treatment.
• The leading Soft Tissue Sarcoma Companies working in the market include Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
• Promising Soft Tissue Sarcoma Pipeline Therapies in the various stages of development include Olaratumab, Pembrolizumab, NBTXR3, Glufosfamide, PXD101, Doxorubicin, and others.
• May 2024:- Institut Claudius Regaud- Phase I Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma. This is a phase I, multicenter, open-label study starting with a dose exploration phase and followed by an expansion phase to evaluate the safety profile and the preliminary activity of the bispecific antibody anti PD-1/CTLA-4 MEDI5752 in combination with SBRT delivered on one lung metastatic lesion, in patients with metastatic soft tissue sarcoma.

Request a sample and discover the recent advances in Soft Tissue Sarcoma @ Soft Tissue Sarcoma Pipeline Outlook Report

Soft Tissue Sarcoma Overview

Soft tissue sarcoma is a disease in which malignant (cancer) cells form in the soft tissues of the body. Having certain inherited disorders can increase the risk of soft tissue sarcoma. A sign of soft tissue sarcoma is a lump or swelling in soft tissue of the body. Soft tissue sarcoma is diagnosed with a biopsy. Soft-tissue sarcomas are a group of cancers that begin in the connective tissues that support and connect the body, including: Blood vessels, Fat cells, Lining of joints, Lymph vessels, Muscle, Nerves and Tendons. As a result, soft-tissue sarcomas can occur almost anywhere in the body.

The Soft Tissue Sarcoma treatment options and prognosis depend on the following: The type of soft tissue sarcoma, the size, grade, and stage of the tumor, where the tumor is in the body, whether all of the tumor is removed by surgery, the patient’s age and general health and whether the cancer has recurred (come back). Small, low-grade tumors, especially in the trunk, arms, or legs, are frequently treated with surgery alone. High-grade sarcomas are more difficult to treat and more likely to spread.

Soft Tissue Sarcoma Emerging Drugs

• AL3818: Advenchen Laboratories

Anlotinib was developed by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. as a new oral molecular RTK inhibitor; it targets VEGFR1, VEGFR3, VEGFR2/KDR, PDGFR-α, c-Kit, and FGFRs 1–3 and inhibits TA and tumor cell proliferation. Anlotinib may inhibit more targets than that do other RTK inhibitors, such as pazopanib, sunitinib, and sorafenib. The main mechanisms of action of anlotinib are as follows: preclinical studies have shown that anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced cell migration, angiogenesis, and capillary-like tube formation in endothelial cells.

• L19 TNF: Philogen

Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). (Recombinant TNF has so far been approved only for certain clinical applications). The fusion of TNF to the L19 antibody specific to the EDB domain of fibronectin results in a tumor-targeted product, which selectively localizes at the site of disease, while sparing healthy organs. Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses.

• Camsirubicin: Monopar Therapeutics

Camsirubicin is a novel proprietary analog of the widely used cancer drug doxorubicin. Camsirubicin has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing the toxic effects on the heart. Preclinical and early clinical studies support the hypothesis that camsirubicin will be less cardiotoxic while retaining anti-cancer activity. Monopar believes the results of these studies, along with the potential to combine a less or non-cardiotoxic analog of doxorubicin with other anticancer agents, emphasizes a large market opportunity for camsirubicin in a broad spectrum of cancer types.

Learn more about Soft Tissue Sarcoma in clinical trials @ Soft Tissue Sarcoma Drugs

Soft Tissue Sarcoma Therapeutics Assessment

There are approx. 125+ key Soft Tissue Sarcoma companies which are developing the therapies for Soft Tissue Sarcoma. The Soft Tissue Sarcoma companies which have their Soft Tissue Sarcoma drug candidates in the most advanced stage, i.e. phase III include, Advenchen Laboratories, LLC.

DelveInsight’s Soft Tissue Sarcoma pipeline report covers around 130+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Discover more about Soft Tissue Sarcoma in development @ Soft Tissue Sarcoma Clinical Trials

Soft Tissue Sarcoma Companies

Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Soft Tissue Sarcoma Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

To know more about Soft Tissue Sarcoma, visit @ Soft Tissue Sarcoma Segmentation

Scope of the Soft Tissue Sarcoma Pipeline Report

• Coverage- Global
• Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Soft Tissue Sarcoma Companies- Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
• Soft Tissue Sarcoma Pipeline Therapies- Olaratumab, Pembrolizumab, NBTXR3, Glufosfamide, PXD101, Doxorubicin, and others.

For further information on the Soft Tissue Sarcoma Pipeline Therapeutics, reach out @ Soft Tissue Sarcoma Products Development

Table of Content

1. Introduction
2. Executive Summary
3. Soft Tissue Sarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Anlotinib: Advenchen Laboratories, LLC
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Camsirubicin: Monopar Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. FHD-609: Foghorn Therapeutics
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Soft Tissue Sarcoma Key Companies
18. Soft Tissue Sarcoma Key Products
19. Soft Tissue Sarcoma- Unmet Needs
20. Soft Tissue Sarcoma- Market Drivers and Barriers
21. Soft Tissue Sarcoma- Future Perspectives and Conclusion
22. Soft Tissue Sarcoma Analyst Views
23. Soft Tissue Sarcoma Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Soft Tissue Sarcoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Small lymphocytic lymphoma Pipeline Report

• DelveInsight’s Small lymphocytic lymphoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Small lymphocytic lymphoma treatment.
• The leading Small lymphocytic lymphoma Companies working in the market include Loxo Oncology, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, and TG Therapeutics represent a diverse array of pharmaceutical companies, each contributing significantly to the advancements in healthcare. Chia Tai Tianqing Pharmaceutical Group, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, and others.
• Promising Small lymphocytic lymphoma Therapies in the various stages of development include ofatumumab, Ibrutinib, Obinutuzumab, Chlorambucil, Arzerra, FC infusion, and others.
• May 2024:- Juno Therapeutics, a Subsidiary of Celgene- An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004). This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose.
• May 2024:- Merck Sharp & Dohme LLC- A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010).
• May 2024:- Inhye Ahn- A Phase 2 Study of Fixed Duration Therapy With Pirtobrutinib and Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (POP). This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).

Request a sample and discover the recent advances in Small lymphocytic lymphoma @ Small lymphocytic lymphoma Pipeline Outlook Report

Small lymphocytic lymphoma Overview

SLL is an indolent (slow growing) non-Hodgkin lymphoma that affects B cells. B cells (also known as B lymphocytes) are specialized white blood cells. Under normal conditions they produce immunoglobulins (also called antibodies) that help protect our bodies against infection and disease. Small lymphocytic lymphoma is considered part of the same disease process as CLL; however, the disease is known as SLL when it involves a lymph node, and CLL when it involves the peripheral blood.

Small lymphocytic lymphoma treatment may involve the use of low or high intensity combination chemotherapy, more recently with a targeted therapy such as a monoclonal antibody. This is commonly known as chemo immunotherapy. The combination of drugs will depend on age, stage of disease and risk factors. Small lymphocytic lymphoma that accumulates in the bone marrow and the spleen can deplete the amount of healthy blood cells in the circulating blood (blood that flows throughout the body).

Small lymphocytic lymphoma Emerging Drugs Profile

• TQ-B3525: Chia Tai Tianqing Pharmaceutical Group

TQ-B3525 is a novel and selective oral PI3K α/δ inhibitor with activity 41 and 138 folds higher than Buparlisib against PI3K α and PI3K δ in pre-clinical research. TQ-B3525 is well-tolerated in Chinese patients with advanced malignancies, and demonstrated high promising antitumor activity in R/R lymphoma patients.Currently,the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.

• LOXO-305: Loxo Oncology

Pirtobrutinib (LOXO-305), is an investigational, oral, highly-selective non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and marginal zone lymphoma.

• IOV 2001: Iovance Biotherapeutics

IOV 2001 is an adoptive cell therapy consist of autologous peripheral blood lymphocytes (PBL) being developed by Iovance Biotherapeutics. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.

Learn more about Small lymphocytic lymphoma in clinical trials @ Small lymphocytic lymphoma Drugs

Small lymphocytic lymphoma Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Small Lymphocytic Lymphoma. The companies which have their Small Lymphocytic Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Loxo Oncology.

DelveInsight’s Small lymphocytic lymphoma pipeline report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Discover more about Small lymphocytic lymphoma in development @ Small lymphocytic lymphoma Clinical Trials

Small lymphocytic lymphoma Companies

Loxo Oncology, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, and TG Therapeutics represent a diverse array of pharmaceutical companies, each contributing significantly to the advancements in healthcare. Chia Tai Tianqing Pharmaceutical Group, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, and others.

Small Lymphocytic Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Small lymphocytic lymphoma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

To know more about Small lymphocytic lymphoma, visit @ Small lymphocytic lymphoma Segmentation

Scope of the Small lymphocytic lymphoma Pipeline Report

• Coverage- Global
• Small lymphocytic lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Small lymphocytic lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Small lymphocytic lymphoma Companies- Loxo Oncology, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, and TG Therapeutics represent a diverse array of pharmaceutical companies, each contributing significantly to the advancements in healthcare. Chia Tai Tianqing Pharmaceutical Group, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, and others.
• Small Lymphocytic Lymphoma Therapies- ofatumumab, Ibrutinib, Obinutuzumab, Chlorambucil, Arzerra, FC infusion, and others.

For further information on the Small lymphocytic lymphoma Pipeline Therapeutics, reach out @ Small lymphocytic lymphoma Products Development

Table of Content

1. Introduction
2. Executive Summary
3. Small Lymphocytic Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Small Lymphocytic Lymphoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug Name : Company Name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. LOXO-305: Loxo Oncology
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase I/II)
14. TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Small Lymphocytic Lymphoma Key Companies
21. Small Lymphocytic Lymphoma Key Products
22. Small Lymphocytic Lymphoma – Unmet Needs
23. Small Lymphocytic Lymphoma – Market Drivers and Barriers
24. Small Lymphocytic Lymphoma – Future Perspectives and Conclusion
25. Small Lymphocytic Lymphoma Analyst Views
26. Small Lymphocytic Lymphoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Small Cell Lung Cancer Pipeline Report

• DelveInsight’s Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment.
• The leading Small Cell Lung Cancer Companies include Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.
• Promising Small Cell Lung Cancer Therapies in the various stages of development include Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, durvalumab, and others.
• May 2024:- UNICANCER- A Phase II Study of Durvalumab (MEDI 4736) Maintenance in Frail Limited Disease Small Cell Lung Cancer Patients After Thoracic Chemoradiotherapy (CRT). This study is an academic-lead, open-label, multicenter, randomized phase II trial for frail limited disease Small Cell Lung Cancer (LD-SCLC) patients.
• May 2024:- Boehringer Ingelheim- DAREONᵀᴹ-8: A Phase I, Open-label, Dose Escalation and Expansion Trial of Repeated Intravenous Infusions of BI 764532 Combined With Standard of Care (Platinium, Etoposide, and Anti-PD-L1) in Patients With Extensive-stage Small Cell Lung Carcinoma.
• May 2024:- Washington University School of Medicine- ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers. In this study, patients with small cell or non-small cell lung cancer will receive ADI-PEG 20, gemcitabine, and docetaxel after demonstrated progression on frontline therapy. In phase I of the study, up to 6 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients enrolling to phase II will be treated at that dose level to assess efficacy.

Request a sample and discover the recent advances in Small Cell Lung Cancer @ Small Cell Lung Cancer Pipeline Outlook Report

Small Cell Lung Cancer Overview

Small cell lung cancer is fast-growing lung cancer that develops in the tissues of the lungs. It is the least common type of lung cancer and characterized by rapid, uncontrolled growth of certain cells in the lungs. Small cell lung cancer (SCLC), previously known as oat cell carcinoma, is considered distinct from other lung cancers, which are called non–small cell lung cancers (NSCLCs) because of their clinical and biologic characteristics.

Small cell lung carcinoma (SCLC) arises in peribronchial locations and infiltrates the bronchial submucosa. Symptoms of SCLC are chest pain, chronic cough, coughing up blood, difficulty breathing, facial swelling, fatigue, hoarseness, loss of appetite, swollen neck veins, weight loss, and wheezing. The standard treatment for first- and second-line management of small cell lung cancer (SCLC) is chemotherapy. Immunotherapy has also made progress in the treatment of SCLC including nivolumab, pembrolizumab, atezolizumab, and durvalumab.

Small Cell Lung Cancer Emerging Drugs Profile

• AMG 757: Amgen

AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer.

• APG-1252: Ascentage Pharma

APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC.

Learn more about Small Cell Lung Cancer in clinical trials @ Small Cell Lung Cancer Drugs

Small Cell Lung Cancer Therapeutics Assessment

There are approx. 100+ key Small Cell Lung Cancer companies which are developing the therapies for Small Cell Lung Cancer. The Small Cell Lung Cancer companies which have their Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Phase III include, Ipsen.

DelveInsight’s Small Cell Lung Cancer pipeline report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Discover more about Small Cell Lung Cancer in development @ Small Cell Lung Cancer Clinical Trials

Small Cell Lung Cancer Companies

Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.

Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Small Cell Lung Cancer Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

To know more about Small Cell Lung Cancer, visit @ Small Cell Lung Cancer Segmentation

Scope of the Small Cell Lung Cancer Pipeline Report

• Coverage- Global
• Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Small Cell Lung Cancer Companies- Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.
• Small Cell Lung Cancer Therapies- Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, durvalumab, and others.

For further information on the Small Cell Lung Cancer Pipeline Therapeutics, reach out @ Small Cell Lung Cancer Products Development

Table of Content

1. Introduction
2. Executive Summary
3. Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Small Cell Lung Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Pembrolizumab: Merck & Co
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Dostarlimab: GlaxoSmithKline
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. AMG 757: Amgen
17. Drug profiles in the detailed report…..
18. Preclinical/Discovery Stage Products
19. S 055746: Vernalis
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Small Cell Lung Cancer Key Companies
23. Small Cell Lung Cancer Key Products
24. Small Cell Lung Cancer- Unmet Needs
25. Small Cell Lung Cancer- Market Drivers and Barriers
26. Small Cell Lung Cancer- Future Perspectives and Conclusion
27. Small Cell Lung Cancer Analyst Views
28. Small Cell Lung Cancer Key Companies
29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Small Cell Lung Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)